Kezar Life Sciences is a clinical-stage biotechnology company, discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. Co.'s primary product candidate, KZR-616, is a selective immunoproteasome inhibitor. KZR-261 is the main clinical candidate from Co.'s research platform targeting the Sec61 translocon and the protein secretion pathway for the discovery and development of small molecule therapeutics for oncology and autoimmune indications. KZR-261 has demonstrated anti-tumor activity in preclinical models of both solid and hematologic malignancies by targeting multiple pathways driving tumor growth and survival. The KZR average annual return since 2018 is shown above.
The Average Annual Return on the KZR average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KZR average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KZR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free KZR Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
